FDA: Majority of Drug Makers Meeting Postmarketing Requirements

Most makers of approved drug and biological products are meeting their regulatory obligations and meeting targets for postmarketing studies/clinical trials in a timely manner, according to a study released by the U.S. Food and Drug Administration (FDA).

The study, based on the second annual review of the status of 1,551 postmarketing studies/clinical trials, showed that 40 percent of the postmarketing studies/clinical trials had been closed (either fulfilled or released) by FDA. Of the remaining 60 percent, most were in progress and on schedule or the final report has been submitted for FDA review.

The review, done under a contract with Booz Allen Hamilton, examined the backlog of industry postmarketing studies and clinical trials for FDA-approved drugs and biologics. The backlog was defined as all those postmarketing requirements (PMR) and postmarketing commitments (PMC) open when the Food and Drug Administration Amendments Act (FDAAA) was enacted on Sept. 27, 2007.

Under the FDAAA, the agency must annually report the status of the backlog of PMR and PMC for all approved drug and biological products. In addition, manufacturers of drugs and biologics are required to report to the FDA in a timely manner any serious safety issues that are identified from studies or other sources.

Key findings of the study include:

  • During the second annual review, the status of 591 PMR/PMCs changed. Nearly half (46 percent) of the PMR/PMCs were updated to fulfilled status, which reflects a significant effort by FDA staff to complete reviews of the large number of submitted final reports identified during the first annual review. Those remaining were updated as a result of study/trial initiation and completion, final report submission or missed milestone dates;
  • Only 17 percent of the backlog of PMRs/PMCs were delayed;
  • Just 7 percent of PMRs/PMCs on schedule after the first annual review became delayed during the second review.

For more information, view "Final Report on the Postmarketing Requirement/Postmarketing Commitment Backlog Review" and "General Information on Postmarketing Requirements/Postmarketing Commitments."

Product Showcase

  • SwabTek® Cannabis Test Kit

    The SwabTek® Cannabis Test Kit is a single-use spot test designed for use in screening for cannabis compounds in any sample type or on any surface. The test is capable of identifying the presumed presence of cannabinoids in very small quantities, with a level of detection as little as 6 μg in mass. Learn more about the SwabTek® Cannabis Test Kit and the rest of SwabTek surface drug testing solutions through the webinar titled "Everything You Want To Know About Surface Testing" Read More

  • Glove Guard® Clip

    Safety should never be compromised, especially when it comes to proper glove usage. The Glove Guard® clip enhances safety by encouraging employees to keep their gloves with them at all times. This reduces the risk of accidents and injuries on the job. By ensuring everyone has their gloves readily available, we help promote a culture of safety and efficiency. The Glove Guard® clip is designed to withstand the toughest work environments. Constructed from robust materials made in the USA, it can endure extreme conditions, including harsh weather, and rigorous activities. Read More

  • HAZ LO HEADLAMPS

    With alkaline or rechargeable options, these safety rated, Class 1, Div. 1 Headlamps provide long runtime with both spot and flood options in the same light. Work safely and avoid trip hazards with flexible hands-free lighting from Streamlight. Read More

Featured

Webinars